Latest Breaking News On - Metastatic castrate resistant prostate - Page 1 : comparemela.com

Syncromune, Inc Announces FDA Clearance of IND Application for SYNC-T SV-102, a First-In-Class Combination Multi-Target Immunotherapy for Metastatic Castrate-Resistant Prostate Cancer

Syncromune, Inc Announces FDA Clearance of IND Application for SYNC-T SV-102, a First-In-Class Combination Multi-Target Immunotherapy for Metastatic Castrate-Resistant Prostate Cancer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesMichael tattoryDanielle hobbsEamonn hobbsDrug administrationCorporate communicationsExchange commissionSyncromune incLifesci communicationsNone of syncromune incMetastatic castrate resistant prostateCharles linkFort lauderdaleSecurities act

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Lynparza approved in EU for prostate cancer

Investegate announcements from AstraZeneca PLC, Lynparza approved in EU for prostate cancer

United statesUnited kingdomTopoisomerase iibetaAdrian kempCompany on twitterEuropean commissionOncology group trialsMerck co incInvestor relations teamEuropean unionMedicinal productsHuman useNew drug applicationPriority reviewPrescription drug user fee actCollaboration revenue

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Lynparza granted FDA priority review for PROpel

Investegate announcements from AstraZeneca PLC, Lynparza granted FDA priority review for PROpel

United kingdomUnited statesEliav barrAdrian kempSusan galbraithCompany on twitterAmerican society of clinical oncologyInternational journal of clinical practiceDrug administrationMerck co incResearch laboratoriesInvestor relations teamHead of global clinical developmentPriority reviewNew drug applicationPrescription drug user fee act

PROpel Phase III trial positive results of Lynparza plus abiraterone in 1st-line metastatic castration-resistant prostate cancer published in New England Journal of Medicine Evidence

Results from the PROpel Phase III trial showed that AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone significantly improved radiographic progression-free survival (rPFS) versus abiraterone alone as a 1st-line treatment for patients with metastatic castration-resistant prostate cancer .

United kingdomUnited statesNoel clarkeEliav barrCristian massacesiCompany on twitterAmerican society of clinical oncologyInternational journal of clinical practiceUniversity of manchesterData monitoring committeeMerck co incResearch laboratoriesInvestor relations teamHead of global clinical developmentNew england journalNeurological surgeon

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Lynparza combo delays progression risk in prostate

Investegate announcements from AstraZeneca PLC, Lynparza combo delays progression risk in prostate

United statesUnited kingdomFred saadRoy baynesAdrian kempSusan galbraithAmerican society of clinical oncologyInternational journal of clinical practiceData monitoring committeeUniversity of montreal hospital centerMerck co incCompany on twitter astrazenecaResearch laboratoriesInvestor relations teamHead of global clinical developmentClinical oncology